Argenx’s Vyvgart Fails Phase 3 Trial for Sjögren’s Disease; FDA Raises Safety Concerns for Evenamide

Argenx reported that its drug Vyvgart failed a Phase 3 trial for Sjögren’s disease, while the FDA flagged a potential safety signal for Evenamide, an investigational drug for treatment-resistant schizophrenia.

Why it matters. Pharmaceutical companies and investors are affected by these setbacks, as they impact drug development timelines and financial projections.